Cigna Ends GLP-1 Obesity Drug Coverage for Employees, Effective July 1
CI is trading near its 52-week low of $239.51 (14% above the low).
Summary
Health insurer Cigna will stop covering GLP-1 weight-loss drugs, including Eli Lilly's Zepbound, for its own employees starting July 1. This policy change, confirmed by a company spokesperson, is a cost-saving measure for Cigna. While specific to its internal employee plan, this decision by a major insurer could signal a broader trend of tightening coverage for expensive GLP-1 medications across commercial health plans, potentially impacting pharmaceutical manufacturers like Eli Lilly (LLY). Traders will watch for any announcements regarding Cigna's broader commercial health plans or similar policy changes from other major insurers.
At the time of this announcement, CI was trading at $272.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $72.1B. The 52-week trading range was $239.51 to $338.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.